Overview

Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study

Status:
NOT_YET_RECRUITING

Trial end date:
2028-12-30

Target enrollment:

Participant gender:

Summary

The purpose of this study is to explore the efficacy and safety of sorafenib combined with venetoclax as pre-emptive therapy strategy for measurable residual disease persisting acute myeloid leukemia.

Phase:

PHASE2

Details

Lead Sponsor:

Nanfang Hospital, Southern Medical University

Treatments:

Sorafenib
venetoclax